to its beneficiaries in a financially sustainable way.

DATES: The Meeting: July 11–12, 2006. The meeting will begin at 9 a.m. on July 11, and 8:30 a.m. on July 12.

Special Accommodations: Persons attending the meeting who are hearing or visually impaired, or have a condition that requires special assistance or accommodations, are asked to notify the Medicaid Commission by June 30, 2006 (see FOR FURTHER INFORMATION CONTACT).

ADDRESSES: The Meeting: The meeting will be held at the following address: Sheraton Crystal City, 1800 Jefferson Davis Highway, Arlington, Virginia 22202, United States, telephone: (703) 486–1111, fax: (703) 769–3970.

Web site: You may access up-to-date information on the Medicaid Commission at http://aspe.hhs.gov/medicaid/.

FOR FURTHER INFORMATION CONTACT: Margaret Reiser, (202) 205–8255.

SUPPLEMENTARY INFORMATION: On May 24, 2005, we published a notice (70 FR 29765) announcing the Medicaid Commission and requesting nominations for individuals to serve on the Medicaid Commission. This notice announces a public meeting of the Medicaid Commission.

Topics of the Meeting

The Commission will discuss options for making longer-term recommendations on the future of the Medicaid program that ensure long-term sustainability. Issues to be addressed may include, but are not limited to: Eligibility, benefit design, and delivery; expanding the number of people covered with quality care while recognizing budget constraints; long term care; quality of care, choice, and beneficiary satisfaction; and program administration.

Procedure and Agenda

This meeting is open to the public. There will be a public comment period at the meeting. The Commission may limit the number and duration of oral presentations to the time available. We will request that you declare at the meeting whether or not you have any financial involvement related to any services being discussed.

After the presentations and public comment period, the Commission will deliberate openly. Interested persons may observe the deliberations, but the Commission will not hear further comments during this time except at the request of the Chairperson. The Commission will also allow an open

public session for any attendee to address issues specific to the topic.

Authority: 5 U.S.C. App. 2, 10(a)(1) and (a)(2).

Dated: June 2, 2006.

Donald A. Young,

Acting Assistant Secretary for Planning and Evaluation, Department of Health and Human Services.

[FR Doc. E6–8993 Filed 6–8–06; 8:45 am] BILLING CODE 5150–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Targeted
Evaluation of the President's
Emergency Plan for AIDS Relief
(PEPFAR) Funded Prevention of
Mother-to-Child HIV Transmission
(PMTCT), and Adherence to
Antiretroviral Therapy (ART) Programs,
Contract Solicitation Numbers (CSN)
2006–N–08428, 2006–N–08429, and
2006–N–08430

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Targeted Evaluation of the President's Emergency Plan for AIDS Relief (PEPFAR) Funded Prevention of Mother-to-Child HIV Transmission (PMTCT), and Adherence to Antiretroviral Therapy (ART) Programs, Contract Solicitation Numbers (CSN) 2006–N–08428, 2006–N–08429, and 2006–N–08430.

Time and Date: 8:30 a.m.–9 a.m., June 27, 2006 (Open). 9 a.m.–6 p.m., June 27, 2006 (Closed).

Place: Renaissance Concourse Hotel—Marriott, One Hartsfield Center Parkway, Atlanta, GA 30354, Telephone 404–209–

Status: The meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to "Targeted Evaluation of the PEPFAR Funded PMTCT, and ART Programs," Contract Solicitation Numbers (CSN) 2006–N–08428, 2006–N–08429, and 2006–N–08430.

For Further Information Contact: Amy L. Sandul, Health Scientist, National Center for HIV, STD, and Tuberculosis Prevention, Centers for Disease Control and Prevention,

1600 Clifton Road NE., MS E-41, Atlanta, GA 30333, Telephone 404.639.6485.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: June 2, 2006.

Alvin Hall.

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E6–8991 Filed 6–8–06; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following Federal Committee meeting.

Name: Advisory Committee on Immunization Practices (ACIP).

Time and Date: 8 a.m.–6 p.m., June 29, 2006. 8 a.m.–4 p.m., June 30, 2006.

Place: Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Building 19, Room 232, Atlanta, Georgia 30333.

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.

Matters to be Discussed: The agenda will include discussions on Human Papillomavirus Vaccine, which will include a VFC Vote; Varicella Virus Vaccine, which will include a VFC Vote; Influenza Vaccine; Mumps Outbreak; Use of Tdap in pregnant women; Adult Immunization Schedule; Pneumococcal Vaccine; Herpes zoster (Shingles) Vaccine; Childhood/Adolescent Immunization Schedule; Immunization Safety; Menactra Supply and Prioritization; Update on Rotavirus Vaccine; and Agency updates. Agenda items are subject to change as priorities dictate.

For Further Information Contact: Demetria Gardner, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE., (E–61), Atlanta, Georgia 30333, telephone 404/639–8096, fax 404/639–8616.